Mission BioCapital

TippingPoint Biosciences is developing therapeutics that target abnormal DNA packaging states in diseases such as cancer.

Cloverleaf Bio specializes in the development of an innovative RNA therapeutic platform focused on oncology. This platform enables the direct inhibition of cancer-promoting enzymes using a single therapeutic molecule, offering a novel approach to improve patient outcomes in cancer treatment.

Aperture Therapeutics is a biotechnology company dedicated to developing novel therapies for age-related neurodegenerative diseases. It employs a distinctive drug discovery platform that leverages the genetic diversity of patients to identify new disease pathways and drug targets. Currently in the pre-clinical stage, the company operates from a lab incubator, integrating insights from neuroscience and immunology to advance its research. Aperture Therapeutics' approach centers on the significance of genetic diversity in the discovery process, aiming to create more effective treatments for neurodegeneration and neuroimmunology conditions.

QurAlis Corporation is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing precision therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. It focuses on drugs that directly target disease-causing genetic alterations using proprietary platforms and biomarkers to identify and treat patients with specific genetic mutations, aiming to halt disease progression and improve outcomes.

Tune Therapeutics develops cell and gene therapies guided by epigenetic programming to treat devastating diseases. The company is building an epigenetic programming platform that enables new pathways for disease treatment by tapping into the epigenome to program biology without altering the DNA sequence. This approach aims to deliver paradigm-changing therapies by modulating gene expression through epigenetic mechanisms rather than editing the genome, expanding options for diseases where conventional treatments have limited efficacy. By integrating epigenetics and cell biology, the company seeks durable, precise interventions that can reprogram cellular states to restore function while minimizing genetic change. The emphasis is on research and development to advance candidates toward clinical use to address severe and unmet medical needs.

Shape Therapeutics, Inc. is a biotechnology company focused on RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic disorders. Founded in 2018 and headquartered in Seattle, Washington, the company utilizes its proprietary RNAfix technology to edit RNA using the body’s natural cellular machinery. This approach minimizes risks associated with immunogenicity, cellular toxicity, and unintended DNA editing. Shape Therapeutics is dedicated to advancing its innovative platforms for payload, delivery, and manufacturing to enable the development of effective treatments, aiming to address critical health challenges and improve patient outcomes.

Glycomine, Inc. is a biotech company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, the company addresses the significant unmet medical needs of patients suffering from rare diseases, of which approximately 7,000 exist globally, with a majority lacking FDA-approved treatments. Glycomine specializes in creating replacement therapies that combine substrates, enzymes, and proteins with advanced bio-nano materials. These therapeutics are designed to facilitate the targeted delivery of treatment to clinically relevant organs, thereby enhancing the efficacy of care for conditions characterized by metabolic disorders and protein misfolding.

Vedere Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on developing gene therapy products aimed at restoring functional vision for patients who have experienced vision loss due to Inherited Retinal Degenerations (IRDs) and other causes of vision impairment, both genetic and non-genetic. Unlike many ocular gene therapies that primarily slow the progression of vision loss, Vedere Bio seeks to restore lost vision, regardless of the patient's genetic background or stage of their condition. As of September 2020, Vedere Bio operates as a subsidiary of Novartis AG.

Caribou Biosciences develops cellular engineering solutions based on CRISPR technologies, offering a gene editing platform with applications in human therapeutics, disease modeling, genomics research, and agricultural biotechnology.

QurAlis Corporation is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing precision therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. It focuses on drugs that directly target disease-causing genetic alterations using proprietary platforms and biomarkers to identify and treat patients with specific genetic mutations, aiming to halt disease progression and improve outcomes.

Shape Therapeutics, Inc. is a biotechnology company focused on RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic disorders. Founded in 2018 and headquartered in Seattle, Washington, the company utilizes its proprietary RNAfix technology to edit RNA using the body’s natural cellular machinery. This approach minimizes risks associated with immunogenicity, cellular toxicity, and unintended DNA editing. Shape Therapeutics is dedicated to advancing its innovative platforms for payload, delivery, and manufacturing to enable the development of effective treatments, aiming to address critical health challenges and improve patient outcomes.

Glycomine, Inc. is a biotech company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, the company addresses the significant unmet medical needs of patients suffering from rare diseases, of which approximately 7,000 exist globally, with a majority lacking FDA-approved treatments. Glycomine specializes in creating replacement therapies that combine substrates, enzymes, and proteins with advanced bio-nano materials. These therapeutics are designed to facilitate the targeted delivery of treatment to clinically relevant organs, thereby enhancing the efficacy of care for conditions characterized by metabolic disorders and protein misfolding.

Vedere Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on developing gene therapy products aimed at restoring functional vision for patients who have experienced vision loss due to Inherited Retinal Degenerations (IRDs) and other causes of vision impairment, both genetic and non-genetic. Unlike many ocular gene therapies that primarily slow the progression of vision loss, Vedere Bio seeks to restore lost vision, regardless of the patient's genetic background or stage of their condition. As of September 2020, Vedere Bio operates as a subsidiary of Novartis AG.

Zymergen, Inc. is a biotechnology company that focuses on researching, developing, and manufacturing microbes for various industries, including agriculture, chemicals, materials, pharmaceuticals, electronics, and personal care. Founded in 2013 and headquartered in Emeryville, California, Zymergen employs a platform that integrates automation, machine learning, and genomics to enhance the efficiency of microbial strain optimization and production processes. This technology enables the company to improve existing manufacturing strains and facilitates the development of new products by engineering novel molecules from microbes. With additional offices in Boise, Idaho; Medford, Massachusetts; Seattle, Washington; and Tokyo, Japan, Zymergen aims to partner with nature to create innovative materials and products that deliver significant value across multiple sectors.

QurAlis Corporation is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing precision therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. It focuses on drugs that directly target disease-causing genetic alterations using proprietary platforms and biomarkers to identify and treat patients with specific genetic mutations, aiming to halt disease progression and improve outcomes.

Sentieon, Inc. is a bioinformatics company based in Mountain View, California, founded in 2014. It specializes in developing and commercializing cloud-based solutions for the life sciences and clinical markets. Sentieon offers a range of bioinformatics tools designed for processing genomics data with a focus on accuracy, efficiency, and quick turnaround times. Its notable products include Sentieon DNAseq, which aids in germline DNA analysis, and Sentieon TNseq, designed for detecting tumor-normal somatic variants. These software-only tools boast scalability and upgradeability, leveraging optimized algorithms to improve computing performance. Sentieon aims to enhance the capabilities of scientists and clinicians by providing precision tools that facilitate comprehensive tumor characterization and other critical bioinformatics processes.